RECBIO
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Clinical Trial Approval For mRNA Covid-19 Vaccine For Omicron Variant In The Philippines 2022-06-27 14:47
Clinical Trial Approval For ReCOV In The PRC And The Overseas Clinical Trial Progress Of ReCOV 2022-05-05 11:55
Receipt Of Approval From The UAE For Phase II/III Clinical Trial Of Sequential Booster Vaccination For ReCOV 2022-04-13 12:56
Successful Passing Of The EU Qualified Person Audit Of The Group's Manufacturing Facility For ReCOV In Taizhou 2022-04-11 16:05
Recbio Announces Proposed Listing on the Main Board of the Hong Kong Stock Exchange 2022-03-21 14:41
Recbio Provides Updates on First Lyophilized mRNA Vaccine and Pre-clinical Data Showing Long-term stability and Strong immunogenicity against SARS-CoV-2 2022-02-15 12:57
The Philippines Has Approved ReCOV For Phase II/III Cinical Trial 2022-01-17 16:57
Recbio Receives Pharmaceutical Production License from Jiangsu Medical Products Administration for Production of COVID-19 Vaccine 2021-11-17 09:00
Recbio Announces Promising Preliminary Results From First-in-Human Study of a COVID-19 Vaccine Candidate With Novel Adjuvant BFA03 2021-11-12 07:55
Recbio Announces New Study Showing Its COVID-19 Vaccine Induced High Levels of Neutralizing Antibodies against SARS-CoV-2 and Variants of Concern 2021-11-09 10:00
1 2